Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) and its subsidiary, Biovest International, Inc. (OTCBB:BVTI), report follow-up data to a Phase 2 trial conducted by the National Cancer Institute (NCI) that shows Biovest's BiovaxID yielded an 89% survival rate in mantle cell lymphoma patients. The median follow-up was 3.8 years. Historically, patients with this type of lymphoma only have had a 50% chance of surviving 3 years and 20% chance of surviving 5 years. BiovaxID, an investigational personalized anti-cancer vaccine, stimulates the immune system to seek out and destroy tumor cells. The data were published in a recent edition of Nature Medicine (Nat Med.2005; 11(9):986-91).

In this single-arm, open-label Phase 2 clinical study, patients with untreated mantle cell non-Hodgkin's lymphoma (NHL) were administered six cycles of dose-adjusted EPOCH-R, a chemotherapy regimen that includes Rituxan (rituximab). Of the 26 patients in the study, 23 received vaccinations with BiovaxID commencing at least three months after completing their last chemotherapy and Rituxan treatments. Upon the 46-month (3.8-year) follow-up, the overall survival rate was 89%. This study showed that, despite an almost complete depletion of normal B-cell lymphocytes due to EPOCH-R therapy, BiovaxID did induce anti-tumor T-cell lymphocyte responses in most patients. Depletion of normal B-cell lymphocytes is a consequence of the combination of chemotherapy and Rituxan, but not of BiovaxID therapy. Thus, "it is justifiable to administer vaccines in the setting of B-cell depletion, but vaccine boosts after B-cell recovery may be necessary for optimal humoral responses," concluded the investigators.

Lymphocytes are a type of white blood cell. There are two types of lymphocytes: B-cell lymphocytes, which produce antibodies ("humoral" immunity) in response to immune stimulation; and T-cell lymphocytes, which mediate cell responses to immune stimulation ("cellular" immunity). B-cell ly
'"/>

Contact: Carl M. Cohen, Ph.D
ccohen@biovest.com
508-793-0001 x 448
The Investor Relations Group
24-Jan-2006

Page: 1 2
Related biology news :

1. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
2. Interim analysis of anti-cancer vaccine, BiovaxID, to be conducted
3. BiovaxID produces long term clinical remission and 95 percent overall survival
4. Lost forest yields several new species
5. Sequencing method yields fuller picture
6. St. Jude study yields secrets of chromosome movement
7. Virus widely used in gene therapy research yields important clues to genomic instability
8. From ink to optics, study of particle mixtures yields fundamental insights
9. Cooperative science program yields results
10. Supermap of avian flu yields new info on source/spread
11. Researchers look into plant cells to increase ethanol yields